Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new inhaled therapy could transform how we treat one of the ICU's deadliest conditions. In a phase 2b trial, EXO-CD24 — an exosome-based immunomodulator — left 85% of ARDS patients free of respiratory failure by day 7, compared to just 33% on placebo. Mortality at 6 months was also dramatically lower: 13.3% vs. 43.3%.
Acute respiratory distress syndrome (ARDS) has long stumped clinicians — few drugs have meaningfully moved the needle. But a new inhaled therapy called EXO-CD24 is turning heads. Presented at the CHEST Annual Meeting, phase 2b results showed that 85% of ARDS patients receiving the twice-daily nebulized treatment were free of respiratory failure by day 7, compared to just 33.3% on placebo.
EXO-CD24 works by harnessing the body's own communication system. Engineered exosomes — tiny natural cargo vesicles — deliver the immunomodulatory protein CD24 directly to lung tissue, dampening damage-driven inflammation while keeping pathogen defenses intact. The treatment was well-tolerated, with no treatment-related serious adverse events across all study phases.
By the Numbers:
Why it matters: ARDS carries a devastating mortality rate, and effective pharmacological treatments have been elusive. EXO-CD24's strong efficacy and safety signals — plus its potential to be adapted for other inflammatory conditions — make it one of the most promising ARDS candidates in years. A phase 3 international trial is on the horizon.